Drug Profile
Ezurpimtrostat - Genoscience
Alternative Names: GNS-561Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Genoscience
- Developer Genfit; Genoscience
- Class Antifibrotics; Antineoplastics; Antivirals; Chlorinated hydrocarbons; Piperidines; Quinolines; Small molecules
- Mechanism of Action Apoptosis stimulants; Autophagy inhibitors; PPT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer; COVID 2019 infections; Liver cancer
- Phase I/II Cholangiocarcinoma
- No development reported Hepatic fibrosis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Cholangiocarcinoma in France
- 28 Dec 2023 No recent reports of development identified for preclinical development in Hepatic-fibrosis in France (Intraperitoneal, Injection)
- 10 Nov 2023 Pharmacodynamics data from a preclinical trial in Hepatocellular carcinoma presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)